- Encouraging clinical data emerging from several phase II trials with highly selective AXL inhibitor bemcentinib (BGB324)
- Advanced lung cancer (NSCLC): First stage fully recruited, and first efficacy endpoint met in phase II trial of bemcentinib in combination with anti-PD-1 therapy KEYTRUDA®
- Advanced leukaemia (AML/MDS): Encouraging bemcentinib single agent activity in hard to treat relapsed / refractory (R/R) leukaemia
- Pipeline update: AXL antibody preparing for Phase I clinical trial
PR Newswire
BERGEN , Norway, 21 Aug, 2018